Rankings
▼
Calendar
TEVA Q1 2023 Earnings — Teva Pharmaceutical Industries Limited Revenue & Financial Results | Market Cap Arena
TEVA
Teva Pharmaceutical Industries Limited
$37B
Q1 2023 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$3.7B
+0.0% YoY
Gross Profit
$1.6B
43.2% margin
Operating Income
-$13M
-0.4% margin
Net Income
-$220M
-6.0% margin
EPS (Diluted)
$-0.20
QoQ Revenue Growth
-5.7%
Cash Flow
Operating Cash Flow
-$145M
Free Cash Flow
-$284M
Stock-Based Comp.
$32M
Balance Sheet
Total Assets
$43.5B
Total Liabilities
$34.8B
Stockholders' Equity
$7.9B
Cash & Equivalents
$2.1B
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$3.7B
$3.7B
+0.0%
Gross Profit
$1.6B
$1.7B
-9.1%
Operating Income
-$13M
-$713M
+98.2%
Net Income
-$220M
-$955M
+77.0%
Revenue Segments
Product
$3.1B
84%
Distribution Service
$434M
12%
Product and Service, Other
$95M
3%
License
$43M
1%
Geographic Segments
North America Segment
$1.8B
51%
Europe Segment
$1.2B
34%
International Markets
$492M
14%
← FY 2023
All Quarters
Q2 2023 →